Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

Background Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There are, however, no data about the use of the XELIRI regimen in the neoadjuvant treatment. Methods Patients with unresectable liver-onl...
Ausführliche Beschreibung

Background Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There are, however, no data about the use of the XELIRI regimen in the neoadjuvant treatment. Methods Patients with unresectable liver-only metastases of MCRC with ≤ 75 years of age were randomised to either the XELIRI (irinotecan 250 mg/$ m^{2} $ given on day one and capecitabine 1000 mg/$ m^{2} $ twice daily from day 2–15, every 21 days) or the FOLFIRI arm (irinotecan 180 mg/$ m^{2} $, 5-FU 400 mg/$ m^{2} $, LV 200 mg/$ m^{2} $, 5-FU 2400 mg/$ m^{2} $ (46-h infusion) – all given on day one, every 14 days). Primary end points were objective response rate (ORR) and rate of radical (R0) surgical resection. Secondary end points were progression-free survival (PFS), overall survival (OS) and safety. Results Altogether 87 patients were enrolled (41 pts in the XELIRI and 46 pts in the FOLFIRI arm). The median age was 63 years (63 years in the XELIRI and 62 years in the FOLFIRI arm) (p = 0.33). ORR was 49% in the XELIRI and 48% in the FOLFIRI arm (p = 0.76). The rate of radical R0 resection was 24% in both arms of patients. At the end of treatment, 37% of patients in the XELIRI and 26% of patients in the FOLFIRI arm were without evidence of the disease (CR+R0 resection) (p = 0.56). There were no statistical differences in grade 3 or 4 adverse events between both arms: diarrhoea 7% vs. 6%, neutropenia 5% vs. 13%, ischemic stroke 0 vs. 2%, acute coronary syndrome 2% vs. 4%, respectively. At the median follow up of 17 (range 1–39) months, the median PFS was 10.3 months in the XELIRI and 9.3 months in the FOLFIRI arm (p = 0.78), the median OS was 30.7 months in the XELIRI arm and 16.6 months in the FOLFIRI arm (p = 0.16). Conclusion The XELIRI regimen showed similar ORR as the FOLFIRI regimen in the neoadjuvant treatment of patients with MCRC. In addition, the XELIRI regimen showed similar PFS and OS with acceptable toxicity compared to the FOLFIRI regimen. Trial Registration Current Controlled Trials ISRCTN19912492 Ausführliche Beschreibung

Autor*in:	Skof, Erik [verfasserIn] Rebersek, Martina Hlebanja, Zvezdana Ocvirk, Janja

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2009

Schlagwörter:	Bevacizumab Liver Metastasis Irinotecan Capecitabine Objective Response Rate

Anmerkung:	© Skof et al; licensee BioMed Central Ltd. 2009. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (

Übergeordnetes Werk:	Enthalten in: BMC cancer - London : BioMed Central, 2001, 9(2009), 1 vom: 22. Apr.
Übergeordnetes Werk:	volume:9 ; year:2009 ; number:1 ; day:22 ; month:04

Links:	Volltext

DOI / URN:	10.1186/1471-2407-9-120

Katalog-ID:	SPR027618803